Is there any role for using Oncotype Dx to decide between neoadjuvant chemotherapy vs. endocrine therapy in a postmenopausal woman with T2N0 ER+,HER2- breast cancer?  

Typically, my decision for NAC is motivated by the following where I'm convinced that there is enough risk that I will give a particular regimen: 1) NAC will help determine later therapy (e.g. triple ngtv and adj capecitabine OR HER2+ and TDM-1) and/or 2) NAC will assist with surgical approach ...